Last updated: February 19, 2026
Who are the main manufacturers of fondaparinux sodium?
Several pharmaceutical companies produce brand-name and generic formulations of fondaparinux sodium, a synthetic pentasaccharide anticoagulant used for deep vein thrombosis, pulmonary embolism, and other thrombotic conditions.
Market Overview
- Major branded product: Arixtra (U.S. brand name manufactured by GlaxoSmithKline).
- Generic producers: Several companies now supply denos and biosimilar options following patent expirations.
Key Suppliers
| Company |
Product Name |
Formulation |
Manufacturing Location |
Market Status |
| GlaxoSmithKline |
Arixtra |
2.5 mg prefilled syringe |
United Kingdom |
Original patent holder; global distribution |
| Mylan |
Fondaparinux Sodium |
Injection |
India, Europe |
Generic; approved in multiple countries |
| Cipla |
Fondaparinux Sodium |
Injection |
India |
Generic; approved in India and some markets |
| Sandoz (Novartis) |
Fondaparinux Sodium |
Injection |
Switzerland |
Biosimilar version; approved in select markets |
| Cipla |
Fondaparinux Sodium |
Injection |
India |
Widely available generics |
Regulatory Approvals & Market Access
- Arixtra: Approved by FDA (2004) and EMA (2004). Widely used globally.
- Generics: Market entry post-patent expiry (2012 for Arixtra in many territories). Approved through local regulatory agencies such as the FDA, EMA, CDSCO (India).
Supply Chain Dynamics
- Major suppliers are concentrated in Europe and India.
- India-based companies like Mylan and Cipla account for significant generics production.
- Supply can be affected by patent litigation, regulatory approvals, and manufacturing capacity constraints.
Price and Procurement Trends
- Private sector procurement favors generics, lowering costs.
- Price variations linked to regional approval status, dosage forms, and manufacturing quality.
- International tenders govern large institutional purchases, notably in healthcare systems of Europe and Asia.
Implications for Stakeholders
- Pharmaceutical companies: Opportunities exist for biosimilar development, contingent on patent rights and regulatory pathways.
- Investors: Focus on companies manufacturing generics, especially in regions with high demand.
- Health authorities: Monitor supply stability and regulatory compliance of suppliers.
Key Takeaways
- GlaxoSmithKline’s Arixtra remains the primary branded source.
- Multiple Indian and European companies supply generics, expanding access and reducing costs.
- Regulatory approvals vary by region, influencing product availability.
- Supply chain challenges include capacity limits and patent disputes.
- The market for fondaparinux sodium is mature, with established generic players dominating procurement.
FAQs
What are the main uses of fondaparinux sodium?
It is used to prevent and treat deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.
Are generics interchangeable with branded formulations?
Yes, if approved through regulatory agencies like the FDA or EMA, generics must meet bioequivalence standards.
What challenges affect the supply of fondaparinux sodium?
Patent restrictions, manufacturing capacity, regulatory delays, and quality control issues.
Which countries have the highest consumption of fondaparinux?
The United States, European Union member states, India, and emerging markets in Southeast Asia.
Are biosimilars available for fondaparinux?
Yes, Sandoz and other companies have developed biosimilar versions approved in select markets.
Citations
- U.S. Food and Drug Administration. (2004). Arixtra approval notice. FDA.
- European Medicines Agency. (2004). Marketing authorization for Arixtra. EMA.
- Indian Drugs Pharmacy. (2021). Cipla’s generic fondaparinux sodium. IDP.
- Novartis. (2020). Sandoz biosimilar fondaparinux sodium. Sandoz.
- MarketWatch. (2022). Global fondaparinux sodium market analysis. MarketWatch.
